FOXO1 and B-cell chronic lymphocytic leukemia: Here, we show that FoxO1 inhibition represents a potential therapeutic target in CLL since it decreases CLL cells’ viability, and this effect is more profound when combined with ibrutinib, acalabrutinib, pirtobrutinib, or idelalisib.